Anne Holck Storås

  • Consultant; MD, PhD
 

Publications 2024

Löffeler S, Bertilsson H, Müller C, Aas K, Haugnes HS, Aksnessaether B, Pesonen M, Thon K, Tandstad T, Murtola T, Poulsen MH, Nordstrøm T, Vigmostad MN, Ottosson F, Holmsten K, Christiansen O, Slaaen M, Haug ES, Storås AH, Asphaug L, Rannikko A, Brasso K, Scandinavian Prostate Cancer Group (SPCG) and the Norwegian Get-Randomized (GRand) Initiative (2024)
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
BJU Int (in press)
DOI 10.1111/bju.16314, PubMed 38469686

Publications 2023

Robsahm TE, Tsuruda KM, Hektoen HH, Storås AH, Cook MB, Hurwitz LM, Langseth H (2023)
Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
Acta Oncol, 62 (1), 8-14
DOI 10.1080/0284186X.2023.2175331, PubMed 36762472

Storås AH, Tsuruda K, Fosså SD, Andreassen BK (2023)
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study
Acta Oncol, 62 (12), 1716-1722
DOI 10.1080/0284186X.2023.2257876, PubMed 37725527

Publications 2022

Fosså SD, Dahl AA, Johannesen TB, Gjelsvik YM, Storås AH, Myklebust TÅ (2022)
Late Adverse Health Outcomes and Quality of Life after curative radiotherapy + long-term ADT in Prostate Cancer Survivors: Comparison with men from the general population
Clin Transl Radiat Oncol, 37, 78-84
DOI 10.1016/j.ctro.2022.08.003, PubMed 36093341

Storås AH, Andreassen BK, Fosså SD (2022)
Characterization of long-term survivors of primary metastatic prostate cancer patients in Norway
Acta Oncol, 61 (5), 615-618
DOI 10.1080/0284186X.2022.2051204, PubMed 35300560

Publications 2021

Storås AH, Fosså SD, Ursin G, Andreassen BK (2021)
Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs
Prostate Cancer Prostatic Dis, 26 (1), 53-58
DOI 10.1038/s41391-021-00445-x, PubMed 34493838

Publications 2019

Storås AH, Sanda MG, Garin O, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD (2019)
A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy
Asian J Urol, 7 (2), 161-169
DOI 10.1016/j.ajur.2019.08.001, PubMed 32257809

Publications 2018

Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, Ferrer F, Boladeras A, Zamora V, Fosså S, Storås AH, Sanda M, Serra-Sutton V, Ferrer M (2018)
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis
Cancer Treat Rev, 66, 23-44
DOI 10.1016/j.ctrv.2018.03.005, PubMed 29673922

Publications 2016

Fosså SD, Storås AH, Steinsvik EA, Myklebust TA, Eri LM, Loge JH, Dahl AA (2016)
Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26)
Scand J Urol, 50 (4), 280-5
DOI 10.3109/21681805.2016.1163617, PubMed 27049891

Publications 2015

Storås AH, Sanda MG, Boronat OG, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD (2015)
Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients
Clin Genitourin Cancer, 14 (3), e265-73
DOI 10.1016/j.clgc.2015.10.009, PubMed 26778476

Publications 2014

Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD (2014)
Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment
Clin Genitourin Cancer, 12 (4), e117-25
DOI 10.1016/j.clgc.2013.12.007, PubMed 24524968

Page visits: 762